Year In Review: Biotech Industry Not As Optimistic About Financing As Analyst Community
Executive Summary
After a bleak 2009, it is not difficult to find market analysts who anticipate a much brighter picture for biotech finance in the new year - but those sentiments are not always echoed by the people on the ground. Venture capitalists and high-ranking biotech executives still see a world of tight money and dubious exit potential for investors with continued reliance on merger and acquisition activity for the near-term